Not to be confused with rotenolone.

Rosterolone (INNTooltip International Nonproprietary Name) (developmental code name SH-434), also known as 17α-propylmesterolone or 1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one, is a steroidal antiandrogen which was first described in 1984 and was developed for topical administration but was never marketed.[1][2] It has shown some efficacy in the treatment of acne, and lacks systemic effects with either topical or systemic administration.[3][1][2] Rosterolone is a derivative of mesterolone, which, in contrast, is an androgen and anabolic steroid.[citation needed]

See also

References

  1. ^ a b Luderschmidt C, Eiermann W, Jawny J, Bidlingmaier F, Ring J (December 1984). "17 alpha-Propylmesterolone (SH 434): an antiandrogenic sebosuppressive substance not influencing circulating testosterone concentrations. Experimental studies in Syrian hamsters". Naunyn-Schmiedeberg's Archives of Pharmacology. 328 (2): 214–8. doi:10.1007/BF00512076. PMID 6527707. S2CID 26451613.
  2. ^ a b Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Current Medicinal Chemistry. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363.
  3. ^ Neumann F, Töpert M (1990). "Antiandrogens and Hair Growth: Basic Concepts and Experimental Research". In Orfanos CE, Happle R (eds.). Hair and Hair Diseases. Springer. pp. 791–826. doi:10.1007/978-3-642-74612-3_34. ISBN 978-3-642-74614-7.